Business
InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabin...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Sept. 25, 2018\n\n\n\nVANCOUVER, Sept. 25, 2018 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has filed a Patent Cooperation Treaty (\"PCT\") application pertaining to the Company's INM-405 program and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which is an important step in protecting the Company's intellectual and commercial property. The patent application, entitled \"Methods and Composition for the Treatment of Pain with Cannabinoids\" is designed to provide protection of the Company's INM-405 program in over 150 different countries including the United States and claims a priority date from September 22, 2017 (PCT/CA202018/051194).\n\n \n \n\n \nDr. Eric Hsu, Ph.D., InMed's Vice President of Preclinical Research and Development commented, \"While there are numerous pharmaceutical products to treat both acute and chronic pain, the increase in the number of prescriptions for the opioid class of products (oxycodone, hydrocodone, morphine, methadone, fentanyl, etc.) has led to concerns as these products can be highly addictive and have damaging side effects, including death.\" According to the United States Centers for Disease Control and Prevention, since 1999, the number of overdose deaths involving opioids (including prescription opioids and heroin) quadrupled, as have the number of prescriptions for opioids, yet there has been no increase in the amount of pain reported in the general population.  Thus, there is a need to find alternative treatments for chronic and severe pain that are non-addictive and have limited side effects. \"InMed is researching the potent...